Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.

Autoria(s): Ruperto N.; Lovell D.J.; Quartier P.; Paz E.; Rubio-Pérez N.; Silva C.A.; Abud-Mendoza C.; Burgos-Vargas R.; Gerloni V.; Melo-Gomes J.A.; Saad-Magalhães C.; Chavez-Corrales J.; Huemer C.; Kivitz A.; Blanco F.J.; Foeldvari I.; Hofer M.; Horneff G.; Huppertz H.I.; Job-Deslandre C.; Loy A.; Minden K.; Punaro M.; Nunez A.F.; Sigal L.H.; Block A.J.; Nys M.; Martini A.; Giannini E.H.; Paediatric Rheumatology International Trials Organization; the Pediatric Rheumatology Collaborative Study Group
Data(s)

2010
Identificador

https://serval.unil.ch/?id=serval:BIB_038A75FF6EF1

isbn:1529-0131[electronic], 0004-3591[linking]

pmid:20191582

doi:10.1002/art.27431

isiid:000279432500031
Idioma(s)

en
Fonte

Arthritis and Rheumatism, vol. 62, no. 6, pp. 1792-1802
Palavras-Chave #Adolescent; Antirheumatic Agents/adverse effects; Antirheumatic Agents/therapeutic use; Arthritis, Juvenile Rheumatoid/drug therapy; Child; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Immunoconjugates/adverse effects; Immunoconjugates/therapeutic use; Methotrexate/therapeutic use; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha/antagonists & inhibitors
Tipo

info:eu-repo/semantics/article

article
Acesso ao item digital